Genome-wide association of the laboratory- based nicotine metabolite ratio in three ancestries

Nicotine and Tobacco Research

Volumn 18, Issue 9, 2016, Pages 1837-1844

  Baurley, James W ^a   Edlund, Christopher K ^a   Pardamean, Carissa I ^a   Conti, David V ^a   Krasnow, Ruth ^b   Javitz, Harold S ^b   Hops, Hyman ^c   Swan, Gary E ^d   Benowitz, Neal L ^e   Bergen, Andrew W ^a  

^a BioRealm LLC   (United States)

^b SRI INTERNATIONAL   (United States)

^c OREGON RESEARCH INSTITUTE   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2A6; NICOTINE;

ADULT; AFRICAN; AGE; ARTICLE; ASIAN AMERICAN; BODY MASS; CONTROLLED STUDY; CYP2A6 GENE; CYP2A7 GENE; EUROPEAN; EUROPEAN AMERICAN; FEMALE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MALE; METABOLITE; NICOTINE METABOLITE RATIO; PREDICTOR VARIABLE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; SEX; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; ASIAN CONTINENTAL ANCESTRY GROUP; BLACK PERSON; CAUCASIAN; GENETICS; GENOME-WIDE ASSOCIATION STUDY; METABOLISM; MIDDLE AGED; TOBACCO DEPENDENCE; TWINS; YOUNG ADULT;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2A6; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; NICOTINE; POLYMORPHISM, SINGLE NUCLEOTIDE; SMOKING; TOBACCO USE DISORDER; YOUNG ADULT;

EID: 84988835607     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntw117     Document Type: Article

References (70)

1. U.S. Department of Health and Human Services. Executive Summary. The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General. Atlanta, GA: United States Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014:36.
2. Bauer UE, Briss PA, Goodman RA, Bowman BA. Prevention of chronic disease in the 21st century: elimination of the leading preventable causes of premature death and disability in the USA. Lancet. 2014;384(9937):45-52.
3. Rostron B. Smoking-attributable mortality by cause in the United States: revising the CDC's data and estimates. Nicotine Tob Res. 2013;15:238-246.
4. Agaku IT, King BA, Dube SR, Centers for Disease Control and Prevention (CDC). Current cigarette smoking among adults-United States, 2005-2012 MMWR Morb Mortal Wkly Rep. 2014;63(2):29-34. www.ncbi. nlm.nih.gov/pubmed/24430098. Accessed October 22, 2015.
5. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108.
6. Underwood JM, Townsend JS, Tai E, et al. Racial and regional disparities in lung cancer incidence. Cancer. 2012;118(7):1910-1918. doi:10.1002/cncr.26479.
7. O'Keefe EB, Meltzer JP, Bethea TN. Health disparities and cancer: racial disparities in cancer mortality in the United States, 2000-2010. Front Public Health. 2015;3:51.
8. Chae DH, Gavin AR, Takeuchi DT. Smoking prevalence among Asian Americans: findings from the National Latino and Asian American Study (NLAAS). Public Health Rep. 2006;121(6):755-763. www.ncbi.nlm.nih. gov/pubmed/17278411. Accessed October 22, 2015.
9. Gorman BK, Lariscy JT, Kaushik C. Gender, acculturation, and smoking behavior among U.S. Asian and Latino immigrants. Soc Sci Med. 2014;106:110-118.
10. Gomez SL, Noone A-M, Lichtensztajn DY, et al. Cancer incidence trends among Asian American populations in the United States, 1990-2008. J Natl Cancer Inst. 2013;105(15):1096-1110.
11. Dempsey D, Tutka P, Jacob P III, et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther. 2004;76(1):64-72.
12. Strasser AA, Benowitz NL, Pinto AG, et al. Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level. Cancer Epidemiol Biomarkers Prev. 2011;20(2):234-238.
13. Derby KS, Cuthrell K, Caberto C, et al. Nicotine metabolism in three ethnic/racial groups with different risks of lung cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(12):3526-3535.
14. Wassenaar CA, Dong Q, Wei Q, Amos CI, Spitz MR, Tyndale RF. Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J Natl Cancer Inst. 2011;103:1342-1346.
15. Rotunno M, Yu K, Lubin JH, et al. Phase I metabolic genes and risk of lung cancer: multiple polymorphisms and mRNA expression. PLoS One. 2009;4(5):e5652.
16. Chen LS, Bloom AJ, Baker TB, et al. Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6). Addiction. 2014;109:128-137.
17. Lerman C, Schnoll RA, Hawk LW Jr, et al. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebocontrolled trial. Lancet Respir Med. 2015;3(2):131-138.
18. Hukkanen J, Jacob P III, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 2005;57(1):79-115.
19. Chen G, Giambrone NE Jr, Dluzen DF, et al. Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms. Cancer Res. 2010;70(19):7543-7552.
20. Rubinstein ML, Shiffman S, Rait MA, Benowitz NL. Race, gender, and nicotine metabolism in adolescent smokers. Nicotine Tob Res. 2013;15(7):1311-1315.
21. Chenoweth MJ, Novalen M, Hawk LW Jr, et al. Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers. Cancer Epidemiol Biomarkers Prev. 2014;23(9):1773-1782.
22. Tyndale RF, Sellers EM. Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Drug Metab Dispos. 2001;29(4 Pt 2):548-552. www.ncbi.nlm.nih.gov/pubmed/11259349. Accessed November 1, 2015.
23. Bough KJ, Lerman C, Rose JE, et al. Biomarkers for smoking cessation. Clin Pharmacol Ther. 2013;93:526-538.
24. Chen L-S, Bierut LJ. Genomics and personalized medicine: CHRNA5-CHRNA3-CHRNB4 and smoking cessation treatment. J Food Drug Anal. 2013;21(4):S87-S90.
25. Swan GE, Lessov-Schlaggar CN, Bergen AW, He Y, Tyndale RF, Benowitz NL. Genetic and environmental influences on the ratio of 3' hydroxycotinine to cotinine in plasma and urine. Pharmacogenet Genomics. 2009;19(5):388-398.
26. Loukola A, Buchwald J, Gupta R, et al. A genome-wide association study of a biomarker of nicotine metabolism. PLoS Genet. 2015;11(9):e1005498.
27. Hamilton DA, Mahoney MC, Novalen M, et al. Test-retest reliability and stability of the nicotine metabolite ratio among treatment-seeking smokers. Nicotine Tob Res. 2015;17(12):1505-1509.
28. Tanner J-A, Novalen M, Jatlow P, et al. Nicotine metabolite ratio (3-hydroxycotinine/cotinine) in plasma and urine by different analytical methods and laboratories: implications for clinical implementation. Cancer Epidemiol Biomarkers Prev. 2015;24(8):1239-1246.
29. Bloom J, Hinrichs AL, Wang JC, et al. The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans. Pharmacogenet Genomics. 2011;21(7):403-416.
30. Patel YM, Stram DO, Wilkens LR, et al. The contribution of common genetic variation to nicotine and cotinine glucuronidation in multiple ethnic/racial populations. Cancer Epidemiol Biomarkers Prev. 2015;24(1):119-127.
31. Vugrin ED, Rostron BL, Verzi SJ, et al. Modeling the potential effects of new tobacco products and policies: a dynamic population model for multiple product use and harm. PLoS One. 2015;10(3):e0121008.
32. Tang H, Abramsohn E, Park H-Y, Cowling DW, Al-Delaimy WK. Using a cessation-related outcome index to assess California's cessation progress at the population level. Tob Control. 2010;19(Suppl 1):i56-i61.
33. Baurley JW, Edlund CK, Pardamean, CI, Conti, DV, Bergen, AW. Smokescreen: a targeted genotyping array for addiction research. BMC Genomics. 2016;17(1):145.
34. Swan GE, Benowitz NL, Jacob P III, et al. Pharmacogenetics of nicotine metabolism in twins: methods and procedures. Twin Res. 2004;7(5):435-448.
35. Swan GE, Hudmon KS, Jack LM, et al. Environmental and genetic determinants of tobacco use: methodology for a multidisciplinary, longitudinal family-based investigation. Cancer Epidemiol Biomarkers Prev. 2003;12(10):994-1005. www.ncbi.nlm.nih.gov/pubmed/14578134. Accessed October 22, 2015.
36. Affymetrix Power Tools. Affymetrix. www.affymetrix.com/estore/partners_ programs/programs/developer/tools/powertools.affx. Accessed October 22, 2015.
37. Minimac3-Genome Analysis Wiki. http://genome.sph.umich.edu/wiki/Minimac3. Accessed October 22, 2015.
38. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol. 2010;34(8):816-834.
39. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38(8):904-909.
40. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26(17):2190-2191.
41. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2014. www.Rproject. org/. Accessed October 22, 2015.
42. Turner SD. qqman: an R package for visualizing GWAS results using Q-Q and manhattan plots. bioRxiv. January 2014:005165.
43. Roadmap Epigenomics Consortium, Kundaje A, Meuleman W, et al. Integrative analysis of 111 reference human epigenomes. Nature. 2015;518(7539):317-330.
44. Ward LD, Kellis M. HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease. Nucleic Acids Res. 2016;44(D1):D877-D881.
45. Zhou X, Maricque B, Xie M, et al. The Human Epigenome Browser at Washington University. Nat Methods. 2011;8(12):989-990.
46. Xiong HY, Alipanahi B, Lee LJ, et al. RNA splicing. The human splicing code reveals new insights into the genetic determinants of disease. Science. 2015;347(6218):1254806.
47. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45(6):580-585.
48. Gauderman WJ. Sample size requirements for matched case-control studies of gene-environment interaction. Stat Med. 2002;21(1):35-50.
49. Suhre K, Raffler J, Kastenmüller G. Biochemical insights from population studies with genetics and metabolomics. Arch Biochem Biophys. 2016. 589:168-176.
50. Bergen AW, Michel M, Nishita D, et al. Drug metabolizing enzyme and transporter gene variation, nicotine metabolism, prospective abstinence, and cigarette consumption. PLoS One. 2015;10(7):e0126113.
51. Deeken J. The Affymetrix DMET platform and pharmacogenetics in drug development. Curr Opin Mol Ther. 2009;11(3):260-268. www.ncbi.nlm. nih.gov/pubmed/19479659. Accessed October 22, 2015.
52. McDonagh EM, Wassenaar C, David SP, et al. PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. Pharmacogenet Genomics. 2012;22(9):695-708.
53. Thorgeirsson TE, Gudbjartsson DF, Surakka I, et al. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet. 2010;42(5):448-453.
54. Kumasaka N, Aoki M, Okada Y, et al. Haplotypes with copy number and single nucleotide polymorphisms in CYP2A6 locus are associated with smoking quantity in a Japanese population. PLoS One. 2012;7(9):e44507.
55. Castaldi PJ, Cho MH, San José Estépar R, et al. Genome-wide association identifies regulatory Loci associated with distinct local histogram emphysema patterns. Am J Respir Crit Care Med. 2014;190(4):399-409.
56. Kaufmann A, Hitsman B, Goelz PM, et al. Rate of nicotine metabolism and smoking cessation outcomes in a community-based sample of treatment-seeking smokers. Addict Behav. 2015;51:93-99.
57. European Commission. Attitudes of Europeans towards Tobacco. 2012. http://ec.europa.eu/health/tobacco/docs/eurobaro_attitudes_towards_ tobacco_2012_en.pdf. Accessed November 4, 2015.
58. Maes HH, Sullivan PF, Bulik CM, et al. A twin study of genetic and environmental influences on tobacco initiation, regular tobacco use and nicotine dependence. Psychol Med. 2004;34:1251-1261. www.ncbi.nlm.nih. gov/pubmed/?term=15697051. Accessed November 1, 2015.
59. Nakajima M, Yamamoto T, Nunoya K, et al. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos. 1996;24:1212-1217 www.ncbi.nlm.nih.gov/pubmed/?term=8937855. Accessed November 1, 2015.
60. Nakajima M, Yamamoto T, Nunoya K, et al. Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes. J Pharmacol Exp Ther. 1996;277:1010-1015. www.ncbi.nlm.nih.gov/pubmed/?term=8627511. Accessed November 1, 2015.
61. Jarvik ME, Madsen DC, Olmstead RE, Iwamoto-Schaap PN, Elins JL, Benowitz NL. Nicotine blood levels and subjective craving for cigarettes. Pharmacol Biochem Behav. 2000;66(3):553-558. www.ncbi.nlm.nih.gov/pubmed/10899369. Accessed November 1, 2015.
62. Cannon DS, Mermelstein RJ, Hedeker D, et al. Effect of neuronal nicotinic acetylcholine receptor genes (CHRN) on longitudinal cigarettes per day in adolescents and young adults. Nicotine Tob Res. 2014;16(2):137-144.
63. Cannon DS, Medina TR, Mermelstein RJ, et al. CYP2A6 longitudinal effects in young smokers. Nicotine Tob Res. 2016;18(2):196-203.
64. Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature. 2008;452:638-642.
65. Saccone SF, Hinrichs AL, Saccone NL, et al. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet. 2007;16:36-49.
66. Gelernter J, Kranzler HR, Sherva R, et al. Genome-wide association study of nicotine dependence in American populations: identification of novel risk loci in both African-Americans and European-Americans. Biol Psychiatry. 2015;77(5):493-503.
67. Hancock DB, Reginsson GW, Gaddis NC, et al. Genome-wide meta-analysis reveals common splice site acceptor variant in CHRNA4 associated with nicotine dependence. Transl Psychiatry. 2015;5:e651.
68. Saccone NL, Culverhouse RC, Schwantes-An TH, et al. Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. PLoS Genet. 2010;6.
69. Hong LE, Yang X, Wonodi I, et al. A CHRNA5 allele related to nicotine addiction and schizophrenia. Genes Brain Behav. 2011; 10(5):530-535.
70. Dempsey DA, St Helen G, Jacob P III, Tyndale RF, Benowitz NL. Genetic and pharmacokinetic determinants of response to transdermal nicotine in white, black, and Asian nonsmokers. Clin Pharmacol Ther. 2013;94(6):687-694.